Genentech (DNA) cancer drug sales disappoint - BloggingStocks

Posted April 11th 2008 11:12AM by Filed under: , , , Shares of biotechnology giant . (NYSE: ) have got been trading slightly less despite the company posting yesterday eventide . Hurting the stock this morning time are the company's gross gross sales of malignant neoplastic disease drugs Avastin, which disappointed analysts.Genentech announced that its net income during the first-quarter rose 12% to $790 million, or 74 cents per share, boosted by strong malignant neoplastic disease drug sales. These Numbers are up from $706 million, or 66 cents a share reported in the same time period a twelvemonth ago. Excluding particular items, the company's net income would have got come up at 84 cents a share, exceeding analysts' prognoses for a quarterly net income of 82 cents a share.The company's quarterly gross saw a growing of 8% to $3.06 billion, up from $2.84 billion a twelvemonth ago. However, this was not adequate to beat out analysts' anticipations for gross gross sales of $3.1 billion in the quarter, according to Virgil Thomson Financial.For this period, the biotechnology company benefited from strong sales of its top-selling cancer drugs, Avastin and Rituxan, which jumped 13%. Gross Sales of Rituxan increased 13% twelvemonth over twelvemonth to $605 million, while malignant neoplastic disease drug Avastin gross gross sales totaled $600 million, but missed analysts' prognosis for $622 million in sales. Analysts were waiting for Genentech to demo higher Avastin gross sales especially after the company won U.S. regulating blessing for the drug as a breast malignant neoplastic disease treatment in February, despite an federal agency panel's ballot for a negative recommendation. Genentech's executive directors believe the weak gross sales Numbers were brought by physicians' safety concerns before the Food and Drug Administration approval. However, they see "all of the signs" as "very good" as the weak gross sales growing came after they "only had the label for four or five hebdomads within the quarter.'' is a fiscal author for the online investing advisory service .

Study: Drug slows breast cancer

By Shari River Rudavsky

A drug that cuts off the blood supply to tumours have been establish to dramatically slow the patterned advance of advanced breast cancer, according to a survey led by an Hoosier State University School of Medicine researcher.

When used in concurrence with chemotherapy, the drug Avastin nearly doubled the amount of clip that women with metastatic disease went without seeing their malignant neoplastic disease grow, the trial of 722 women found.

The study, whose consequences were first presented at a 2005 conference and are published in today's New England Diary of Medicine, showed the most important benefits ever associated with using Avastin to handle breast cancer.

Avastin, approved to handle advanced colorectal and lung cancer, forestalls the development of new blood vas that malignant neoplastic diseases trust on to flourish.

Women treated with chemotherapy alone saw their malignant neoplastic diseases advancement within an norm of 5.9 calendar months after starting treatment. Those who had Avastin added to their regimen went 11.8 calendar months without disease progression.

Even the study's writers were surprised by the magnitude of the results.

"I expected that adding Avastin to treatment would do treatment more effective," said Dr. Kathy Miller, Pb writer and the Sheila D. Ward Scholar at the IU School of Medicine. "I don't believe anyone expected the difference to be this huge. This is a larger difference than we've seen with any other treatment."

However, Avastin did not have got a important impact on overall survival, the survey found.

Citing Avastin's failure to widen survival, an consultative commission to the Food and Drug Administration this calendar month narrowly voted against approving it to handle breast cancer.

The commission also referred to the drug's possible side personal effects when making the decision. In surveys other than the 1 Glenn Miller just published, Avastin have been associated with an increased opportunity of blood coagulums and death.

The Food and Drug Administration is expected to do a concluding opinion in February.

Physicians such as as Dr. Sumeet Bhatia, a medical oncologist with Community Regional Cancer Care who have been using Avastin for his patients with advanced disease for the past two years, establish the consultative committee's opinion surprising.

"I was a small puzzled by this because I thought it was a place tally when I first proverb it (the data) in 2005," Bhatia said. "A batch of us believe this plant in the metastatic setting. It is not the lone thing you do, but it's another utile tool."

Avastin may win in preventing breast malignant neoplastic disease on respective fronts, Glenn Glenn Glenn Glenn Miller said.

Not only will it detain the growing of new blood vessels, it also may do malignant neoplastic disease cells more than sensitive to chemotherapy and encouragement the immune system, giving the organic structure another defence against the cancer.

Despite the consultative committee's ballot of no confidence, Miller said she thought the drug could profit many women with advanced breast cancer.

"I believe this gives those women a new and much more effectual option than we have got got ever had," said Miller, also an associate professor of medical specialty at the School of Medicine.

Now, Miller and co-workers desire to cognize whether Avastin will have a similarly good consequence for women with malignant neoplastic disease that's not as advanced.

She's leading a survey that in the adjacent 21/2 old age will inscribe 4,950 patients to see whether early treatment with Avastin will diminish the opportunity of a recurrence.